HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-11-2004, 07:21 PM   #1
eric
Guest
 
Posts: n/a
http://biz.yahoo.com/prnews/041211/sfsa001_1.html

Dendreon Corporation (Nasdaq: DNDN - News) today announced results from two Phase 1 studies demonstrating promising clinical activity of the company's investigational immunotherapy, APC8024, in HER2/neu positive advanced breast cancer. Michelle Melisko M.D., Clinical Instructor, Carol Franc Buck Breast Care Center, University of California Comprehensive Cancer Center, San Francisco, presented the findings today at the 27th Annual San Antonio Breast Cancer Symposium.

"APC8024 represents the expansion of our immunotherapy platform into other solid tumors," said Robert Hershberg, M.D., Ph.D., senior vice president and chief medical officer at Dendreon Corporation. "We believe APC8024 could provide physicians with a highly targeted and well-tolerated therapy for treating patients with breast cancer. Based on the encouraging data from these two Phase 1 studies, we are planning to initiate a Phase 2 trial with APC8024 in metastatic breast cancer in the coming year."
  Reply With Quote
Old 12-12-2004, 08:51 AM   #2
imported_Joe
Guest
 
Posts: n/a
Eric,

We met with representatives od Dendereon at the San Antonio Breast Cancer Symposium. They are soon be recruiting for their Phase II clinical trials and will notify our group when they are ready.

They have a toll free number to call for information:

1-866-477-6782 ext: 3

Regards
Joe

Denderon Web Site
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:42 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter